Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Nature reviews. Cancer - 1 May 2015

Ratner Nancy, Miller Shyra J

Abstract excerpt

Neurofibromatosis type 1 (NF1) is a common genetic disorder that predisposes affected individuals to tumours. The NF1 gene encodes a RAS GTPase-activating protein called neurofibromin and is one of several genes that (when mutant) affect RAS-MAPK signalling, causing related diseases collectively known as RASopathies. Several RASopathies, beyond NF1, are cancer predisposition syndromes. Somatic NF1 mutations also...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, ras
Share to Genes, Tumor Suppressor
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to GTPase-Activating Proteins

Share to Mutation

Share to Neurofibromatosis 1

Share to Neurofibromin 1

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 25877329
DOI: 10.1038/nrc3911
PMCID: PMC4822336

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.PMID 25877329Read ↗

Neurofibromatosis type 1: diagnosis and recent advancesSemantic proximity Read ↗

Neurofibromatosis 1.Semantic proximity Read ↗

Emerging therapeutic targets for neurofibromatosis type 1Semantic proximity Read ↗

Neurofibromatosis Type 1: Piecing the Puzzle TogetherSemantic proximity Read ↗

The NF1 somatic mutational landscape in sporadic human cancers.Semantic proximity Read ↗

Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenuesSemantic proximity Read ↗

Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.Semantic proximity Read ↗

RAS and beyond: the many faces of the neurofibromatosis type 1 proteinSemantic proximity Read ↗

Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathies.Semantic proximity Read ↗

Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.Semantic proximity Read ↗

Neurofibromatosis Type 1: Pathology, Clinical Features and Molecular GeneticsSemantic proximity Read ↗

Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.